Amolyt Pharma

Edit info

Founded: 2018

Location: Ecully, France

Employee range: 11 - 50

Clinical stage: Clin2

Therapy area: Hypoparathyroidism

Drug types: END, BON

Lead product: Eneboparatide

Funding: $138M C Jan 2023; $80M B Sep 2021; $75M A Aug 2019

Investors: Sectoral Asset Management, Andera Partners, ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital, Credit Agricole Creation, Intermediate Capital Group, Sofinnova Partners

amolytpharma.com

linkedin.com

job board

Drug notes:

AZP-3813 Clin0 acromegaly; AZP-40XX RD/Clin0 hyperparathyroidism, humoral hypercalcemia of malignancy

About:

Amolyt Pharma, a clinical stage, global biotech company founded in 2014, is developing innovative therapeutic strategies for patients who suffer from rare endocrine and metabolic diseases. Their therapeutic pipeline includes treatments for hypoparathyroidism, acromegaly, and humoral hypercalcemia of malignancy. Their team has significant expertise in developing therapeutic peptides. Amolyt Pharma won “Biotech Company of the Year” award at the 2023 LSX European Lifestars Awards.

Jobs:

Main

Contact: recruit@workinbiotech.com